This is a free sample of content from Aging: The Longevity Dividend.
Click here for more information on how to buy the book.

Index

A

AD. *See* Alzheimer's disease
ADIPOQ, exceptional longevity studies in humans, 98
Adult neurogenesis. *See* Neural stem cell
Age-related macular degeneration (AMD), genetics and pathophysiology, 82
Aging, definition, 232–233
AGPAT2, 79
AGS. *See* Aicardi–Goutieres syndrome
Aicardi–Goutieres syndrome (AGS), overview, 70, 75
Alzheimer's disease (AD)
  unimodal antigeroid alleles, 83–84
  unimodal progeroid syndrome, 79–80
AMD. *See* Age-related macular degeneration
AMP kinase
  conserved longevity pathways, 32
  metformin activation, 180–181
  network theory of aging, 38
  therapeutic targeting in aging, 101
Amyloid-β precursor protein (APP), 79, 85
APC, 82
APOC-3, exceptional longevity studies in humans, 98
APOE2, 83–84
APOE4, 80, 83–84
Aspirin, longevity effects, 123
AT. *See* Ataxia telangiectasia
Ataxia telangiectasia (AT), overview, 70, 77
Atherosclerosis
  unimodal antigeroid alleles, 84–85
  unimodal progeroid syndrome, 83
ATM, 60–61, 77

B

Base excision repair. *See* DNA damage
BCSL. *See* Berardinelli–Seip congenital lipodystrophy
Berardinelli–Seip congenital lipodystrophy (BCSL), overview, 70, 79
β-adrenergic signaling, chronic activation in cardiac aging, 154
BLM, 72–73
Bloom syndrome
  atypical syndrome, 74–76
  overview, 70, 72
BSCL2, 79

C

Caenorhabditis elegans
  aging model overview, 27
  conserved longevity pathways, 28–37
  metformin studies, 182
  mitochondrial stress in aging, 34–35
Calorie restriction (CR)
  cardiac aging studies, 154–155
  longevity effects, 123
  mechanisms of action, 169–171, 174
  metformin comparison in mice, 183, 185
Cardiac aging
  heart disease delay economic impact, 200
  animal models, 150
  interventions
    calorie restriction, 154–155
    growth differentiation factor 11, 157
    microRNA targeting, 157
    mitochondrial interventions, 155
    prospects, 158
    rapamycin, 155
    renin angiotensin aldosterone system inhibition, 156–157
    stem cell therapy, 157–158
  molecular mechanisms
    altered nutrient and growth signaling, 150–151
    calcium homeostasis, 153
    extracellular matrix remodeling, 152–153
    microRNA, 154
    mitochondrial dysfunction, 151–152
    neurohormonal signaling chronic activation, 153–154
  overview, 149–150
Catalase, mitochondrial expression and longevity, 36
CAV1, 79
CCL11, neural stem cell aging studies, 19
Cellular senescence
  aging, 57, 123
  mTOR signaling, 170–171
CETP
  exceptional longevity studies in humans, 98
  therapeutic targeting in aging, 100
Clinical trials, longevity agents
  biomarker types, 127–128
  diseases related to fundamental aging processes, 126
  drug development paradigms and targets
    geriatric syndromes, 125–126

© 2016 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Aging: The Longevity Dividend.
Click here for more information on how to buy the book.

Clinical trials, longevity agents (*Continued*)
localized conditions resembling accelerated aging, 126–127
multiple comorbidities, 125
otherwise fatal conditions, 125
resilience decrease, 126
initial scenarios, 124–125
investigator training, 129
phases, 128–129
preclinical studies, 127
prospects, 129–130
translatable interventions, 123–124
translational research phases, 129
CNBP, 79
Cockayne syndrome (CS)
aging, 53–54
overview, 70, 77–78
Competing risks, aging science studies, 232–235
Connective tissue growth factor (CTGF), cardiac aging role, 153–154
CR. *See* Calorie restriction
CS. *See* Cockayne syndrome
CSA, 54, 78
CSB, 54, 78
CTGF. *See* Connective tissue growth factor

D

DCX. *See* Doublecortin
Dehydroepiandrosterone sulfate (DHEA-S), frailty studies, 139–140
Delayed aging
economic impact. *See* Economic impact, delayed aging
implications
chronic disease morbidity, 215
disability, 214–215
prospects for study, 216–217
DHEA-S. *See* Dehydroepiandrosterone sulfate
Diabetes
frailty role, 139–140
metformin therapy. *See* Metformin
DJ1, 81
DMPK, 79
DNA damage
consequences, 53
free radical theory of aging, 8–9, 56
geroscience focus, 8–9
mitochondrial DNA damage
cardiac aging role, 151–152
frailty role, 139
mitochondrial dysfunction and energy homeostasis, 57–61
neurodegenerative disease and premature aging, 53–54
reactive oxygen species in formation, 52
repair pathways, 52–53
theory of aging, 55–56
therapeutic targeting
base excision repair, 61–62
PARP1, 62–63
DNA ligases, base excision repair, 61
Dog. *See* Longevity dividend
Doublecortin (DCX), adult neurogenesis studies, 19
Drosophila melanogaster
aging model overview, 27–28
conserved longevity pathways, 28–37
metformin studies, 182–183

E

ECM. *See* Extracellular matrix
Economic impact, delayed aging
cancer costs, 198
prospects for study, 206–207
scenarios
aging delay with eligibility fix, 200–203
cancer delay, 200
heart disease delay, 200
overview, 199–200
status quo, 200
single-disease model challenges, 198–199
value of aging delay, 203–206
Epigenetics, geroscience focus, 7–8
Exceptional longevity. *See* Longevity
Exercise. *See* Physical activity
Extracellular matrix (ECM), remodeling in cardiac aging role, 152

F

Fanconi anemia, overview, 70, 78
FOXO3a, exceptional longevity studies in humans, 97
Frailty
criteria, 137
pathophysiology, 138–142
phenotype, 137
therapeutic interventions
implications of complex system dysregulation, 142
physical activity, 142–145
vicious cycle, 138
Free radical theory of aging, 8–9, 56

G

GDF11. *See* Growth differentiation factor 11
Geroscience
overview, 2–6
research areas
epigenetics, 7–8
inflammation, 6, 7

© 2016 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Aging: The Longevity Dividend.
Click here for more information on how to buy the book.

macromolecular damage, 8–9
metabolism, 8
proteostasis, 9
stem cells and regeneration, 9–10
stress adaptation, 7
GH. *See* Growth hormone
Glycosylated hemoglobin (HbA1C), frailty studies, 139–140
Growth differentiation factor 11 (GDF11)
adult neurogenesis studies, 19
cardiac aging studies, 157
Growth hormone (GH)
cardiac aging role, 151
insulin-like growth factor-1 signaling axis, 30
knockout mouse studies of aging, 33–34, 37
network theory of aging, 37

H

HbA1C. *See* Glycosylated hemoglobin
Healthy life expectancy (HLE)
aging distinguishing from disease, 136–137
aging effects, 122–123
chronic disease indicators and health risk factors, 212–213
functional mobility-based indicators, 211–212
healthy life extension overview, 192–194, 210
importance in longevity, 133–134
instruments, 211
limits, 122
overview, 122
physiological status indicators, 213
socioeconomic and racial differences, 213–214
statistical analysis, 225
Heart. *See* Cardiac aging
Heterogeneity aging rate hypothesis, 235–236
HGPS. *See* HGPS
HIF-1. *See* Hypoxia-inducible factor 1
HLE. *See* Healthy life expectancy
Hutchinson–Gilford progeria syndrome (HGPS)
aging, 53
overview, 70, 76–77
rapamycin therapy, 171
Hypoxia-inducible factor 1 (HIF-1), aging studies, 35

I

IGF-1. *See* Insulin-like growth factor 1
Induced pluripotent stem cell (iPSC), aging studies, 10
Inflammation
frailty role, 138
geroscience focus, 6, 7
Insulin resistance (IR), frailty role, 138–141
Insulin-like growth factor 1 (IGF-1)
cardiac aging role, 150–151, 154
conserved longevity pathways, 32–34
exceptional longevity studies in humans, 97–99
frailty decrease, 138, 140
growth hormone signaling axis, 30, 32–33
network theory of aging, 37
receptor, 33
therapeutic targeting in aging, 100–101
iPSC. *See* Induced pluripotent stem cell
IR. *See* Insulin resistance

L

Laminopathy, progerias, 70, 74
LD. *See* Longevity dividend
LGP. *See* Longevity Genes Project
Life expectancy. *See* Healthy life expectancy; Longevity
Life history, populations aged 65+ in three time periods
1965, 225–226
2015, 226–227
2040, 227–228
LKB1, metformin effects, 180–181
LMNA, 74, 76–77, 83, 171
Longevity
exceptional longevity in humans
drug development, 99–101
gene discovery, 98–99
genome-wide association studies, 96–97
rationale for study, 93–95
heritability evidence, 95–96
Hispanic impact on American demographics, 231–232
prospects in 2040, 228–230
socioeconomic status disparities, 230–231
statistical analysis
healthy life expectancy, 225
life expectancy, 224
population distribution
age, 221–222
race, 221
survival, 224–225
translatable interventions, 123
Longevity dividend (LD)
dog model
delayers, escapers, and survivors, 116
limitations, 116–117
morbidity analysis, 111–112
mortality rate analysis, 110–111
prospects, 117–118
rationale, 109
reproduction and sterility, 114–116
variability of phenotypes and genotypes, 109–110
VetCompass database, 112–114
Longevity Dividend Initiative Consortium, 192
objections
infirmity increase, 195

© 2016 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Aging: The Longevity Dividend.
Click here for more information on how to buy the book.

Longevity dividend (LD) (*Continued*)
population growth, 194–195
religious objections, 194
overview, 107–109
rationale, 195–196
Longevity Genes Project (LGP), 98
LRRK2, 81

M

Matrix metalloproteinases (MMPs), cardiac aging role, 153
MD. *See* Myotonic dystrophy
MDPL syndrome, overview, 70, 74–75
Mechanistic target of rapamycin (mTOR). *See also* Rapamycin
cardiac aging role, 150–151
conserved longevity pathways, 28–29
dietary interventions for mTORC1 inhibition, 173–174
mTORC complexes, 166
network theory of aging, 37
prospects for study, 174
protein quality regulation, 170
protein translation regulation, 169–170
Metformin
geroprotective studies
invertebrates, 182–183
mice, 183–185
indications, 179
longevity effects, 123, 181–182
mechanism of action, 180–181
prospects for study in mice, 185–186
therapeutic targeting in aging, 101
MFN2, 59
Micronutrient deficiency, frailty role, 139
MicroRNA, cardiac aging studies
role, 154
therapeutic targeting, 157
Mitochondrial DNA damage. *See* DNA damage
Mitophagy, mitochondrial DNA damage, 58–59
MMPs. *See* Matrix metalloproteinases
Mouse
aging model overview, 28
conserved longevity pathways, 28–37
mTOR. *See* Mechanistic target of rapamycin
Myotonic dystrophy (MD), overview, 70, 78–79

N

NAD^+, supplementation, 62–63
Neural stem cell (NSC)
adult neurogenesis, 16–17
aging effects
cell-intrinsic changes, 18
niche
systemic factors, 18
vascular niche, 19–21
overview, 17–18
systemic circulation studies, 18–19
NIX, 59
Nrf2, aging studies, 36
NSC. *See* Neural stem cell

O

Oligodendrocyte progenitor cell (OPC), aging, 19
OPC. *See* Oligodendrocyte progenitor cell
Osteoporosis, genetics and pathophysiology, 82–83
Oxidative phosphorylation, mitochondrial dysfunction and energy homeostasis, 57–58

P

p53, cellular senescence mediation, 57
PAPR-1, exceptional longevity studies in humans, 97
Parkin, 59, 81
Parkinson's disease (PD), genetics and pathophysiology, 80–81
PARP. *See* Poly(ADP-ribose) polymerase
PCG-1α, cardiac aging role, 152
PCSK9, 84–85
PD. *See* Parkinson's disease
PEPCK. *See* Phosphoenolpyruvate carboxykinase
Phosphoenolpyruvate carboxykinase (PEPCK), metformin effects, 181
Physical activity
frailty intervention, 142–145
mechanisms of benefits, 144
PINK1, 59, 81
PMK-1, aging studies, 36
POLD1, 74–75
POLH, 75
Poly(ADP-ribose) polymerase (PARP)
DNA damage response, 60–61
hyperactivation of PARP1, 60
therapeutic targeting of PARP1, 62–63
PON1, exceptional longevity studies in humans, 97
Population growth, life extension implications, 194–195
Progeroid syndromes. *See specific syndromes*
Programmed (adaptive) theory of aging, 54
PS1, 80
PS2, 80
PTRF, 79

R

RAAS. *See* Renin angiotensin aldosterone system
Race
Hispanic impact on American demographics, 231–232
socioeconomic status disparities in health care and longevity, 213–214, 230–231

© 2016 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Aging: The Longevity Dividend.
Click here for more information on how to buy the book.

Rapamycin
cancer studies, 168–169
cardiac aging studies, 155
clinical trials, 124
intermittent treatment, 172–173
longevity effects, 123, 166–168
mechanisms of action, 165–168
side effects, 171–172
RAS. *See* Ruijs–Aalfs syndrome
Reactive oxygen species (ROS)
DNA damage. *See* DNA damage
free radical theory of aging, 8–9, 56
mitochondrial stress and antioxidants in conserved longevity pathways, 34–37
RECQL4, 73–74
Religious objections, life extension, 194
Renin angiotensin aldosterone system (RAAS), cardiac aging studies
chronic activation, 153–154
inhibition studies, 156–157
Resveratrol
clinical trials, 124
longevity effects, 123
ROS. *See* Reactive oxygen species
Rothmund–Thomson syndrome (RTS), overview, 70, 73–74
RTS. *See* Rothmund–Thomson syndrome
Ruijs–Aalfs syndrome (RAS), overview, 70, 75

S

SAMHD1, 75
Sch9, yeast mutant studies, 29
Secular aging rate hypothesis, 235
SERCA2, cardiac aging role, 153
SES. *See* Socioeconomic status
Sirtuins
conserved longevity pathways, 29–32
network theory of aging, 37–38
SIRT1 exceptional longevity studies in humans, 99
types and functions, 31–32
SKN-1, aging studies, 36
Socioeconomic status (SES), disparities in health care and longevity, 213–214, 230–231
SPARC, cardiac aging role, 153
SPRTN, 75
SS-31, cardiac aging studies, 156
Stem cell
depletion in aging, 57
niche. *See* Neural stem cell
therapy for cardiac aging, 157–158
Stress
geroscience focus on adaptation, 7
telomere shortening, 9

T

Telomere shortening
stress response, 9
telomere theory of aging, 56–57
Testosterone, frailty studies, 138–140
TGF-β. *See* Transforming growth factor-β
Transforming growth factor-β (TGF-β), cardiac aging role, 152–153
TREX1, 75
Trisomy 8, mosaicism, 76
TSHR, exceptional longevity studies in humans, 98

U

UCHL1, 81
Unfolded protein response (UPR), aging studies, 9, 35
UPR. *See* Unfolded protein response
USP47, 62

V

Vascular endothelial growth factor (VEGF), adult neurogenesis role, 17–18, 21
VEGF. *See* Vascular endothelial growth factor
VetCompass Programme, 112
Veterinary Medical Database (VMDB), 111, 114, 116–117
VMDB. *See* Veterinary Medical Database

W

Werner syndrome (WS)
aging, 53–54
overview, 70–72
WRN, 54, 71–72, 74–76, 83

X

Xeroderma pigmentosa (XP), genetics and pathophysiology, 81
XP. *See* Xeroderma pigmentosa
XPA, 59
XPB, 78
XPD, 78
XPG, 78

Y

Yeast
aging model overview, 26–27
conserved longevity pathways, 28–37

© 2016 by Cold Spring Harbor Laboratory Press. All rights reserved.

This is a free sample of content from Aging: The Longevity Dividend.
Click here for more information on how to buy the book.

© 2016 by Cold Spring Harbor Laboratory Press. All rights reserved.